Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Status:
Terminated
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of buparlisib when given together
with ofatumumab or ibrutinib in treating patients with chronic lymphocytic leukemia that has
returned after a period of improvement or does not respond to treatment. Buparlisib and
ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth. Monoclonal antibodies, such as ofatumumab, may block cancer growth in different ways
by targeting certain cells. Giving buparlisib or ibrutinib and ofatumumab together may work
better in treating patients with chronic lymphocytic leukemia.